(Q34452529)

2 August 2017

1 reference

title

Virus population dynamics, fitness variations and the control of viral disease: an update (English)

1 reference

2 August 2017

1 reference

Mónica Gutierrez-Rivas

0 references

Esteban Domingo Solans

1

object named as

Esteban Domingo

0 references

Antonio Mas

2

object named as

Antonio Mas

0 references

Luis Menéndez-Arias

7

object named as

Luis Menéndez-Arias

0 references

author name string

Domingo E

1

1 reference

2 August 2017

Mas A

2

1 reference

2 August 2017

Yuste E

3

1 reference

2 August 2017

Pariente N

4

1 reference

2 August 2017

Sierra S

5

1 reference

2 August 2017

Gutiérrez-Riva M

6

1 reference

2 August 2017

Menéndez-Arias L

7

1 reference

2 August 2017

Eloisa Yuste

3

0 references

Nonia Pariente

4

0 references

Saleta Sierra

5

0 references

Mónica Gutiérrez-Rivas

6

0 references

publication date

1 January 2001

1 reference

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques

2 August 2017

2001

0 references

published in

1 reference

2 August 2017

57

1 reference

2 August 2017

77-115

1 reference

LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression

2 August 2017

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Escape of human immunodeficiency virus from immune control

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Quasispecies in viral persistence and pathogenesis of hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Mutation rates among RNA viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Molecular intermediates of fitness gain of an RNA virus: characterization of a mutant spectrum by biological and molecular cloning

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Detection and quantification of hepatitis C virus RNA replication in the liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Viral dynamics in human immunodeficiency virus type 1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Decay characteristics of HIV-1-infected compartments during combination therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Rapid viral quasispecies evolution: implications for vaccine and drug strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Rabies virus quasispecies: implications for pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Hepatitis C virus resistance to antiviral therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Memory in viral quasispecies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Viruses at the edge of adaptation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

The accuracy of reverse transcriptase from HIV-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

T cell responses and viral escape

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Quantifying the uncertainty in forecasts of anthropogenic climate change

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Viral dynamics in HIV-1 infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Lifespan of human lymphocyte subsets defined by CD45 isoforms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

A national tissue bank to track HIV eradication and immune reconstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Production of resistant HIV mutants during antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

RNA virus mutations and fitness for survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Multidrug Resistance Genotypes (Insertions in the β3–β4 Finger Subdomain and MDR Mutations) of HIV-1 Reverse Transcriptase from Extensively Treated Patients: Incidence and Association with Other Resistance Mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Prevention and treatment of influenza

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Exploring models of the influenza A M2 channel: MD simulations in a phospholipid bilayer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

pH-dependent tetramerization and amantadine binding of the transmembrane helix of M2 from the influenza A virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Incidence of amantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Treating influenza with zanamivir

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Influenza virus neuraminidase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

31 March 2020

Picornavirus inhibitors

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Antiviral therapy for enteroviruses and rhinoviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Structure of the RNA-dependent RNA polymerase of poliovirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Mechanism of action of a pestivirus antiviral compound

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Quasispecies nature of three maize streak virus isolates obtained through different modes of selection from a population used to assess response to infection of maize cultivars

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Antiviral therapy of herpes simplex

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Quantitative analysis of genomic polymorphism of herpes simplex virus type 1 strains from six countries: studies of molecular evolution and molecular epidemiology of the virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Evidence for control of herpes simplex virus mutagenesis by the viral DNA polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Ultraviolet reactivation of herpes simplex virus is mutagenic and inducible in mammlian cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Generation of genetic diversity in herpes simplex virus: An antimutator phenotype maps to the DNA polymerase locus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

An altered spectrum of herpes simplex virus mutations mediated by an antimutator DNA polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Difference in incidence of spontaneous mutations between Herpes simplex virus types 1 and 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of alpha-like DNA polymerases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Foscarnet-resistant herpes simplex virus infection in patients with AIDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

The herpesvirus proteases as targets for antiviral chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Identification of four conserved motifs among the RNA-dependent polymerase encoding elements

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Long-term therapy of chronic hepatitis B with lamivudine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Mutational analysis of Phe160 within the "palm" subdomain of human immunodeficiency virus type 1 reverse transcriptase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Clinical experience with famciclovir against hepatitis B virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Viral genetic variation: hepatitis B virus as a clinical example

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Mutation rate of the hepadnavirus genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Viral dynamics in hepatitis B virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Virus dynamics and drug therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Novel compounds in preclinical/early clinical development for the treatment of HIV infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

New targets for inhibitors of HIV-1 replication

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Lethal mutagenesis of HIV with mutagenic nucleoside analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-8308-5_2

10.1007/978-3-0348-8308-5_2

31 March 2020

Identifiers

DOI

0 references

1 reference